$20.98
-0.64 (-2.96%)
Open$21.50
Previous Close$21.62
Day High$22.23
Day Low$20.76
52W High$28.41
52W Low$1.03
Volume—
Avg Volume3.44M
Market Cap3.39B
P/E Ratio—
EPS$-0.87
SectorBiotechnology
Analyst Ratings
Strong Buy
18 analysts
Price Target
+34.6% upside
Current
$20.98
$20.98
Target
$28.24
$28.24
$22.54
$28.24 avg
$42.65
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 86.69M | 63.79M | 421.41M |
| Net Income | -141,186,978 | -93,508,190 | -114,600,480 |
| Profit Margin | -162.9% | -154.7% | -27.2% |
| EBITDA | -145,836,172 | -101,953,317 | -127,773,532 |
| Free Cash Flow | — | — | -89,915,808 |
| Rev Growth | +35.9% | +35.9% | +7.1% |
| Debt/Equity | — | — | 0.61 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |